Our recent study proved that fusion of HN3(an excellent affiliative antibody for GPC3 [19, 20]) with exosomes derived from epithelial cells could advance liver cancer cell targeting specificity and thus could positively enhance the anti-cancer effect of sorafenib on GPC3 over expressed liver cancer cells [21]. The gene discussed is GPC3; the disease is liver cancer.